[EN] (HETERO) ARYLACETAMIDE DERIVATIVES AS ANTIRETROVIRAL AGENTS<br/>[FR] DÉRIVÉS DE (HÉTÉRO)ARYLACÉTAMIDE SERVANT D'AGENTS ANTIRÉTROVIRAUX
申请人:GILEAD SCIENCES INC
公开号:WO2014110297A1
公开(公告)日:2014-07-17
Compounds of formula (I): or pharmaceutically acceptable salts thereof are disclosed. Also disclosed are pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula (I), intermediates useful for preparing compounds of formula I and therapeutic methods for treating a Retroviridae viral infection including an infection caused by the HIV virus.
Compounds of formula I:
or pharmaceutically acceptable salts thereof are disclosed. Also disclosed are pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I and therapeutic methods for treating a Retroviridae viral infection including an infection caused by the HIV virus.
Compounds of formula I:
or salts thereof are disclosed. Also disclosed are pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I and therapeutic methods for treating a Retroviridae viral infection including an infection caused by the HIV virus.
AMIDE COMPOUNDS FOR THE TREATMENT OF HIV INFECTIONS
申请人:Gilead Sciences, Inc.
公开号:EP3409667A1
公开(公告)日:2018-12-05
Compounds of formula (IIId) or salts thereof are disclosed. Also disclosed are pharmaceutical compositions comprising a compound of formula IIId, processes for preparing compounds of formula IIId, intermediates useful for preparing compounds of formula IIId and therapeutic methods for treating a Retroviridae viral infection including an infection caused by the HIV virus.
本发明公开了式(IIId)化合物或其盐类。还公开了包含式 IIId 化合物的药物组合物、制备式 IIId 化合物的工艺、用于制备式 IIId 化合物的中间体以及治疗逆转录病毒科病毒感染(包括 HIV 病毒引起的感染)的治疗方法。
Imidazolepyridine compounds and uses thereof
申请人:Novartis AG
公开号:US10676479B2
公开(公告)日:2020-06-09
A compound of Formula (IA), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating a PRC2-mediated disease or disorder:
wherein A, R3, R4, R6, and R7 are as defined herein.